Creative Planning
ITRM

Creative Planning’s Iterum Therapeutics ITRM Stock Holding History

Creative Planning’s Portfolio ITRM Stock Details ITRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-872
Closed -$18K – 2323
2021
Q1 		$18K Buy
+872
New +$20.8K ﹤0.01% 2444

Other funds holding ITRM

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CPX
Canaan Partners X Menlo Park, California $74.7M AUM 151.56% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
KFS
Kelly Financial Services Braintree, Massachusetts $467M AUM 21.13% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
QI
QS Investors New York $8.47B AUM 30.71% 1-Year Est. Return
FNBT
FineMark National Bank & Trust Fort Myers, Florida $3.2B AUM 18.28% 1-Year Est. Return
GC
Grimes & Company Westborough, Massachusetts $4.62B AUM 29.71% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Creative Planning's ITRM Position: Q2 2021 in Review

Creative Planning sold out of Iterum Therapeutics (ITRM) in Q2 2021, closing a stake of 872 shares — an estimated $18K sold.

Creative Planning first reported a position in ITRM in Q1 2021 and held it in 1 quarter. The position peaked at $18K in Q1 2021. 44 funds tracked by Wall St. Rank hold ITRM as of Q2 2021.

  • Creative Planning reported no remaining Iterum Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Creative Planning sold 872 Iterum Therapeutics shares in Q2 2021, an estimated $18K.
  • Creative Planning first reported a position in Iterum Therapeutics in Q1 2021 and held it in 1 quarter.
  • Creative Planning's Iterum Therapeutics position peaked at $18K in Q1 2021.
  • 44 funds tracked by Wall St. Rank held Iterum Therapeutics as of Q2 2021.

Based on Creative Planning's 13F filing for Q2 2021, filed 4 Aug 2021.